# Kyowa Kirin Co., Ltd. clinical trials: 159 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 159 trials with Kyowa Kirin Co., Ltd. as lead sponsor, 7 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Kyowa Kirin Co., Ltd.: 159 rows for $7.95, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/kyowa-kirin-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 159
- Recruiting or not yet: 7
- Read on: November 19, 2026

## Trials

The 25 newest of 159, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| June 5, 2026 | NCT07629726 | A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms | Kyowa Kirin Co., Ltd. | Phase 1/2 | Recruiting | Hematologic Neoplasms | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629726) |
| June 3, 2026 | NCT07623616 | A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | Kyowa Kirin Co., Ltd. | Phase 2 | Recruiting | Acute Myeloid Leukemia (AML) | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623616) |
| August 20, 2025 | NCT07132567 | Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance | Kyowa Kirin Co., Ltd. | Observational | Recruiting | Mycosis Fungoides, Sezary Syndrome | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07132567) |
| April 13, 2025 | NCT06926491 | Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study） | Kyowa Kirin Co., Ltd. | Phase 3 | Active not recruiting | Achondroplasia | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926491) |
| February 12, 2025 | NCT06823947 | Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension | Kyowa Kirin Co., Ltd. | Phase 1 | Recruiting | Healthy Volunteers Essential Hypertension | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06823947) |
| February 6, 2025 | NCT06812104 | Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies. | Kyowa Kirin Co., Ltd. | Phase 1 | Recruiting | Relapsed or Refractory AML and Other Hematologic Malignancies | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06812104) |
| July 29, 2024 | NCT06525636 | A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia | Kyowa Kirin Co., Ltd. | Phase 1/2 | Recruiting | X-linked Hypophosphatemia | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06525636) |
| February 20, 2024 | NCT06266299 | A Study of KK2269 in Adult Participants With Solid Tumors | Kyowa Kirin Co., Ltd. | Phase 1 | Active not recruiting | Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06266299) |
| February 8, 2024 | NCT06248411 | A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors | Kyowa Kirin Co., Ltd. | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumors | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06248411) |
| November 3, 2023 | NCT06116916 | Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema | Kyowa Kirin Co., Ltd. | Phase 2 | Active not recruiting | Diabetic Macular Edema (DME) | 185 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06116916) |
| November 3, 2023 | NCT06116890 | Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration | Kyowa Kirin Co., Ltd. | Phase 2 | Completed | Neovascular Age-Related Macular Degeneration (nAMD) | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06116890) |
| June 8, 2022 | NCT05411016 | A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus | Kyowa Kirin Co., Ltd. | Phase 1 | Completed | Healthy Volunteers, Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE) | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05411016) |
| May 3, 2022 | NCT05357573 | Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO | Kyowa Kirin Co., Ltd. | Phase 4 | Completed | Tumor-Induced Osteomalacia (TIO) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05357573) |
| August 16, 2021 | NCT05007652 | A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma | Kyowa Kirin Co., Ltd. | Phase 2 | Completed | Multiple Myeloma and Malignant Lymphoma | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05007652) |
| May 3, 2021 | NCT04870346 | Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia | Kyowa Kirin Co., Ltd. | Observational | Active not recruiting | Aplastic Anemia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04870346) |
| April 12, 2021 | NCT04842032 | Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH | Kyowa Kirin Co., Ltd. | Phase 4 | Completed | X-linked Hypophosphatemia (XLH) | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04842032) |
| April 12, 2021 | NCT04842019 | Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH | Kyowa Kirin Co., Ltd. | Phase 4 | Completed | X-linked Hypophosphatemia (XLH) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04842019) |
| February 25, 2021 | NCT04771780 | Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis | Kyowa Kirin Co., Ltd. | Phase 3 | Completed | Hyperphosphatemia | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04771780) |
| February 23, 2021 | NCT04767581 | Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis | Kyowa Kirin Co., Ltd. | Phase 3 | Completed | Hyperphosphatemia | 165 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04767581) |
| February 23, 2021 | NCT04766398 | Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis | Kyowa Kirin Co., Ltd. | Phase 3 | Completed | Hyperphosphatemia | 169 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04766398) |
| February 23, 2021 | NCT04766385 | Clinical Study of KHK7791 in Hyperphosphatemia Patients on Peritoneal Dialysis | Kyowa Kirin Co., Ltd. | Phase 3 | Completed | Hyperphosphatemia | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04766385) |
| November 3, 2020 | NCT04614298 | A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque Psoriasis | Kyowa Kirin Co., Ltd. | Phase 4 | Withdrawn | Moderate to Severe Plaque Psoriasis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04614298) |
| October 20, 2020 | NCT04594681 | A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration | Kyowa Kirin Co., Ltd. | Phase 1 | Terminated | Healthy Volunteers, Wet Age-related Macular Degeneration | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04594681) |
| August 31, 2020 | NCT04533581 | Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma (NHL) | Kyowa Kirin Co., Ltd. | Phase 2 | Active not recruiting | Indolent B-cell Non-Hodgkin's Lymphoma | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04533581) |
| April 29, 2020 | NCT04368403 | A Study of KHK4827 in Patients With Systemic Sclerosis | Kyowa Kirin Co., Ltd. | Phase 1 | Completed | Systemic Sclerosis | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04368403) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 50 |
| Phase 1/2 | 8 |
| Phase 2 | 39 |
| Phase 2/3 | 6 |
| Phase 3 | 45 |
| Phase 4 | 5 |
| Not applicable | 1 |
| Observational | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 130 |
| Terminated | 14 |
| Recruiting | 7 |
| Active not recruiting | 6 |
| Available | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Parkinson Disease | 20 |
| Familial Hypophosphatemic Rickets | 10 |
| Diabetes Mellitus, Type 2 | 9 |
| Neoplasms | 8 |
| Hyperparathyroidism, Secondary | 7 |
| Hyperphosphatemia | 7 |
| Psoriasis | 6 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Lymphoma, T-Cell, Peripheral | 4 |
| Multiple Myeloma | 4 |
| Anemia, Aplastic | 4 |
| Renal Insufficiency, Chronic | 3 |
| Diabetes Mellitus | 3 |
| Kidney Diseases | 3 |
| Leukemia, Myeloid, Acute | 3 |
| Breast Neoplasms | 3 |
| Cancer Pain | 3 |
| Disseminated Intravascular Coagulation | 3 |
| Leukemia-Lymphoma, Adult T-Cell | 3 |
| Alzheimer Disease | 3 |
| Pain | 3 |
| Dermatitis, Atopic | 3 |
| Oncogenic osteomalacia | 3 |
| Lymphoma | 3 |
| Diabetic Nephropathies | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Air duct cleaning companies in the United States](https://specstream.ai/data/businesses/air-duct-cleaning-companies/united-states)
- [Russian restaurants in the United States](https://specstream.ai/data/businesses/russian-restaurants/united-states)
- [Maternity centers in the United States](https://specstream.ai/data/businesses/maternity-centers/united-states)
- [Fertility clinics in the United States](https://specstream.ai/data/businesses/fertility-clinics/united-states)
- [Burger restaurants in the United States](https://specstream.ai/data/businesses/burger-restaurants/united-states)
- [Vascular medicine practices in the United States](https://specstream.ai/data/businesses/vascular-medicine-practices/united-states)
